Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Camurus, Audiocast with teleconference, Q1'24

By Inderes5/8/2024, 12:00 PM
Camurus

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

John
00:00 - 02:48

Good day everyone, and thank you for taking the time to join our first earnings call for 2024. Before starting the presentation, please note our forward-looking statements. The agenda for today's call includes first quarter financial highlights and results. We will then move to commercial and pipeline updates and finish off with a Q&A. With me on the call today, as previously, are John Gray, our Chief Financial Officer, and Richard Jameson, our Chief Commercial Officer. Starting out with our highlights for the quarter, Camurus had a productive first quarter with strong profitability and pipeline progress. Total revenues grew by 37% year-on-year to 390 million SEK, which is the midpoint of our provided guidance, with profit before tax in the quarter close to 100 million SEK. Our financial position was further strengthened by a successful directed share issue to support inorganic growth opportunities, accelerate US commercial preparations for CAM2029 in neuroendocrine tumors and polycystic liver disease, and enhance our manufacturing capabilities. From a commercial perspective, we continued to strengthen our leading position in opioid use disorder treatment across geographies. Overall sales increased by 29% year-on-year to 364 million SEK at reported rates. In the US, we recently showed strong and accelerating growth, resulting in an approximate threefold increase in sales and royalties in the first quarter versus Q4 2023. On the R&D side, we received FDA acceptance for the review of our NDA for Oclaiz in acromegaly with a decision date in October this year. A corresponding application has now been submitted to the EMA and outside the region. We progressed the Sorrento Study of CAM2029 in neuroendocrine tumors and completed patient recruitment in the Positano trial in polycystic liver disease. Importantly, we also advanced several early development programs, including completing pre-clinical assessments of a novel monthly formulation of semaglutide. Based on the data received. We are preparing for a first clinical study planned to be started towards the end of this year. With this short introduction, I will hand over to John for the financials.

John Gray
02:49 - 07:14

Thanks a lot, Fredrik, and good afternoon everyone. During this quarter, Camurus continued its development, delivering strong profitability and remaining on track to meet the 2024 market guidance and 2027 vision. I would like to share now key highlights of our financial performance this quarter. Camurus achieved 390 million total revenue in the quarter, delivering a growth of 37% versus the same period last year, with product sales of 364 million SEK, growing 29% versus the prior year and basically aligning with the prior quarter. True, the current depreciation has negatively impacted reported figures by 1% year-on-year and by 3% versus the prior quarter. Predictably, sales in the US represented 26,000,006 in royalty income in the quarter following its commercial launch last September. Company profit before taxes was 97 million SEK, achieving an earnings per share after dilution of 1.32 Swedish kronor, equivalent to a profit after tax of 78 million SEK for the quarter. Finally, our cash position progressed positively during the quarter, ending at 2.3 billion SEK, including 1026 million obtained from a directed share issue carried out in January of the size of 2 million shares. Moving to the next slide, we can see the main components of our profit before taxes. The company's gross margin reached 92.1% in the quarter, representing an improvement of 222 basis points versus the same period last year. The improvement was driven by three major factors. Firstly, supply chain efficiencies driven by increased volumes scale up represented 200 basis points. Secondly, 60 basis points are driven by Saudi royalties. And thirdly, it represented a negative impact of -45 basis points. Total OpEx reached 289 million, representing a 57% increase versus the same period in the prior year, driven by the following factors. Marketing and distribution investments supported market penetration in owned territories. Expansion of operations into new markets, including the U.S. Operations grew 23% to 93 million. Administrative expenses, aligned with corporate evolution, substantiate company development and grew 73% versus the same period last year to 16 million. R&D investments reached 180 million SEK, growing 81% versus the same period last year, driven by recruitment completion in the Positano trial. And progress in our preclinical and clinical pipeline. Company profit before taxes reached 97 million SEK, growing 26% versus the prior year. Company cash position at quarter end was 2.3 billion SEK. Camurus improved its cash position in the second quarter, driven by the following factors. Firstly, company operations generated 139 million. Secondly, working capital increased by 102 million. Driven mainly by inventory and receivables growth. Certainly, the company carried out a direct share issue, providing net proceeds of 1026 million after transaction costs. And finally, the company executed the AGM 2021 authorization to hedge employee stock options. Social security cost amounted to 22 million. Assertion of quarter end cameras has no depth. All in all, Camurus closes the first quarter of 2024. With a strengthened financial position, interesting growth opportunities, and is on track to deliver 2024 market guidance. Having said that, I would like to pass the word to Richard. Thank you everyone for your attention.

Richard Jameson
07:16 - 11:10

Thank you, John. So we move over to a commercialization update where I will start in the Camurus markets, and then I'll give an update on Brixadi in the US. So in quarter one, invoice sales for Buvidal grew by plus 29% versus the previous year and 30% at constant exchange rates, and plus 3% versus Q4 at constant exchange rates. After a strong Q4, we saw softer sales in January and February. However, as expected in March, rather, we exited the quarter strongly. Importantly, though, underlying in-market demand remains strong and grew at 5% quarter over quarter, which more accurately reflects performance in the countries. Sharpened execution of our strategies and plans by the team across countries is driving both access to Buvidal and penetration in clinics and criminal justice settings, and we continue to hear of the positive impact the model is having on treatment outcomes for patients with opioid use disorder. To give some more granularity, we had good progress in the UK where in-market we continue to grow in high single digits and recruit new patients alongside accelerating access in criminal justice settings as NHS funding comes through. So that said, this was tempered slightly by delays in that NHS funding due to the NHS year end that finished in March. In Australia, the recent government changes have reduced co-pay for patients, and we see both numbers in treatment and the numbers of long-acting injectable buprenorphine growing. And we maintain our strong leadership in the long-acting buprenorphine segment with patient share above 80%. Also, in the Nordics, France, Spain, and the minor region, all grew well in the quarter, and we remain on track with our market guidance for product sales. We now estimate we have more than 50,000 patients being treated with Buvidal at the end of the quarter, which is approaching 30% of the group. An orphan segment where we have access, though, of course, with an estimated 750,000 patients in treatment in Europe and Australia. There remains a large opportunity for Buvidal in the region. We also continue to expand geographically and in Q1 achieved reimbursement approval in Ireland, which will allow us to expand our use in treatment clinics across the country. And we have ongoing processes for both reimbursement and market authorizations in other countries. Now moving to the US with the launch phase of Brixadi and performance in the quarter in the US. So accelerated penetration, as shown by the large increase in our royalty stream from partner Braeburn; royalty for the quarter was 26 million SEK and based on information from Braeburn, after about six months since launch there, we already have an estimated 7,000 patients on treatment. This excellent early progress reflects the acceptance of the strong product profile and demand for Brixadi in the country with a high unmet medical need. The compelling messaging around Brixadi is clearly resonating with us. Healthcare professionals and Braeburn continue to focus on the launch strategy and execution with a commercial team of more than 100 people, and they have strong payer coverage already on par with other long-acting injectable products in OUD and channels, and a channel development that provides quick and reliable access to Brixadi. And based on the strong performance of Brixadi in the US, our expectations of reaching peak sales above 1 billion dollars has been reinforced. We also continue to build and share the evidence base to highlight the advantages Buvidal brings for those seeking treatment for opioid use disorder and data that supports a differentiated product profile. Firstly, a recent publication on opioid blockade affirms the need to individualize treatment and titrate doses for optimal treatment outcomes and demonstrated blockade across the dose range for both Buvidal and Brixadi. Other publications from Australia show how long-acting buprenorphine is individualized in the country, with broad utilization of all treatment doses in rural clinical practice. So on that note, I will hand back to Fredrik for an update on the pipeline.

John
11:11 - 17:29

Thank you so much, Richard, and I'll give a late-stage development update. Uh, and focusing here on CAM2029. Uh, during the quarter, we continued to advance CAM2029 across target indications, which are acromegaly, gastrointestinal pancreatic neuroendocrine tumors (GEP-NET), and, of course, as you have heard previously here, polycystic liver disease (PLD). And the product is designed for both enhanced efficacy, improved patient convenience, and also quality of life. As our clinical program has progressed with positive study data outcomes. Our expectations for CAM2029 across the indications have been reinforced. So, um. Moving to a short update on each program in acromegaly. We have completed treatment of all patients in acromegaly over to our long-term safety and efficacy study, and will provide updated study results at the end of the second quarter. Building on the previously communicated positive interim results. In parallel, the FDA review of our case has been progressing, and we recently submitted a corresponding market authorization application for CAM2029 to the European Medicines Agency. In GEP-NET after completing enrollment at the end of last year, we are now collecting data and monitoring progression-free survival events until we reach the target of 194. To read out the primary superiority endpoint. In PLD, we completed during the quarter enrollment of all 72 patients in the randomized, placebo-controlled Positano trial, whose primary endpoint is to demonstrate reduced liver volume and improved symptoms in patients with symptomatic polycystic liver disease. So we continue to meet our objectives and timelines for CAM2029 across indications, and have several important milestones ahead of us in the coming year. These include final results from the core phase of Inova, which we expect to be able to present at the end of June, and FDA approval decisions for acromegaly by the 21st of October 2024, followed by the planned US launch of Oclaiz for the treatment of acromegaly in the US around the year end. In general, we are expecting to finalize the core phase of the Sorrento trial in the first half of 2025, and thereafter obtain top line results on the progression-free survival and other key endpoints. This will and should allow an NDA submission to the FDA sometime during the second half of next year and an application in other geographies. They would, of course, follow as closely as possible. Finally, topline results from Positano published in the indication are expected in early 2025. So, parallel with the advances of the registration programs, we continue to build our U.S. Commercial organizations are preparing for the planned localized launch. The estimated market opportunity for CAM2029 across indications is significant and estimated in the region of about 1.5 billion USD. During the period, we started onboarding key functions in medical affairs, marketing, and commercial. We also signed the lease for our new office space in Princeton, New Jersey. Market research has been ongoing, primarily for the acromegaly and GEP-NET indications. Providing insight on patient, prescriber, and payer perspectives, and enabling the team to build out their launch plan. We have also been active with payer engagement and setting up the distribution and patient support model. Medical affairs activities have been accelerated this quarter and this has been reflected. In the number of events that we are participating in, Camurus and study investigators are sharing data from the CAM2029 program and updating on end-to-end positional trials at scientific meetings throughout 2024. To begin our conference schedule, we are including the European Congress of Endocrinology in Stockholm next week, and later in May, we will attend the annual meeting in Boston, which starts on the 30th of May this year. So with that, uh, a short update on the business of Camurus. I'm pleased with the performance of our teams and the partners that we are working with. Continuing execution, which in the quarter has delivered revenues and profitability in line with guidance, robust market growth for Buvidal and a very strong momentum for Brixadi in the US, which we are very pleased with. The NDA was accepted for review by the FDA, and we are on track for an anticipated approval decision in October. In parallel, we have made significant progress on other pipeline programs, including the ones I mentioned earlier today, and Camurus ended the quarter with a strengthened cash position of 2.3 billion SEK to support future organic growth and also inorganic initiatives. So with that, I thank you for your attention and I leave it over to Annette here to please start out the Q&A.

Annette
17:31 - 17:41

Thanks. If you wish to ask a question, please press Pound Key five on your telephone keypad. The first question comes from the line of Echo Code from Canada. Please go ahead. Your line is open.

17:45 - 19:08

Yes. I have a few, if I may. First on Buvidal, the base quarterly patient growth slowed to 2K from being stable at 3K the past two years. And I think you mentioned a UK funding delay, but I assume it can't explain the full delta. So can you please provide some color here? And more specifically, are you starting to see a saturation in some of the early launch markets? And then I have two questions on the monthly summer project. Uh, first, have you looked into preclinical models to see whether your fluid crystal technology can enable higher exposure of Selma versus the original product in animals? And I think as a reference with Doctor Tiberg, you achieved higher exposure with CAM2029 compared to Sounders in LA. And so I was just wondering if this could be the case as well for Selma. And just a short final one then. When do you plan to publicly share the preclinical data generated on the monthly SEM? Uh, today. Thank you.

John
19:11 - 19:17

Thank you. So, I think we'll let Richard start with the question about the softening in January and February.

Richard Jameson
19:18 - 19:59

Yes. I'm happy to say that, um, yes. We did see a slight slowdown in the first two months of the quarter. Partly, as we said, it's the UK funding delay and some of the changes happening in Australia. Overall, I think it's just a slight slowdown for that quarter. We're back to growth now. We exited the quarter strongly. And we believe that we're going to pick up that growth rate the same as before. I don't think it's about saturation. As I said, there are a lot of patients needing treatment in Europe. And we still have a long way to go and a lot of opportunity there. And I think we're seeing increasing demand from patients for long-acting treatments as well. So we only see that accelerating in the future.

John
20:02 - 21:15

Okay. Uh, moving over to your question about higher exposure? I think what we see is that we have quite good flexibility in terms of exposure. And I can say that I don't think that's a limiting aspect for our technology in terms of semaglutide. So, I mean, there are many other considerations, of course, in this treatment. And they have to be considered, but I think we can say with strong confidence that we can provide significant overall exposure during the treatment period. Whether or not from a bioavailability perspective, because that's the difference we are seeing in the CAM2029 case. I don't think I can give you the indication that we have significantly better bioavailability because here we're comparing a non-formulated essentially non-formulated system which theoretically should have 100% bioavailability compared to a formulated system. Is that? Yeah. Your question is.

21:16 - 21:32

Yeah. So you mean, in terms of bioavailability, it's fair to assume that there will be some type of trade-off when switching to a formulated version such as the monthly version.

John
21:32 - 22:10

So it's fair to note. No. I don't think that assumption is correct; on the contrary. I mean, with CAM2029, we essentially have 100% bioavailability. So, we don't have, I would say, that improved bioavailability is something I cannot confirm. Right. I think my message is that we can reach therapeutic levels. Across the current dose range.

22:14 - 22:15

All right. Thank you.

Annette
22:18 - 22:22

The next question is from Brian Baldwin from Jefferies. Please go ahead. Your line is open.

Brian
22:25 - 23:10

Hey. Thank you, guys. The first question is about Brixadi. It had a strong launch. I couldn't see anything in the release, but I just wanted to check if you saw any impact from the change. There was a healthcare cyberattack on Brixadi invoicing and new patient starts, as an individual had reported that to be the case for them. Again, on that GLP-1 phase one study. So, I guess, what is the limit to the molecular size with your liquid crystal technology? Could you potentially go greater than 40 amino acids? And then just on the study, it was just partnered with Novo Nordisk. And if so, what are the economics? And I've got a third question, but I'll stop there for now.

John
23:12 - 23:55

Okay. So, if we start with your first question here, I don't think we have seen or heard any reports that we had any impact from the cyber attack. On the other hand. So, this has not been anything that we have been communicated by our partner in the US. Now, we haven't asked specifically about this topic, but we haven't heard any information about that. So when it came to. Yeah. The second topic. Can you?

John Gray
23:55 - 23:58

The second topic is the limit of molecule size.

John
23:58 - 24:36

Oh yeah. So yeah. Sorry. I mean, I think we have successfully formulated and performed preclinical studies for peptide or small protein compounds, at least up to 20 kilodaltons. But you know, it's always difficult to generalize, but that's of course much more than 30 amino acids. Um, so that is not the limit. Uh, always when you're talking about these things, you have to consider many different aspects. But I would say that we are not limited to 30 amino acids, for instance.

John Gray
24:36 - 24:39

And the third question is regarding partnership. No.

John
24:39 - 24:52

Yes. I mean, we have not announced anything about partnering or relationships with other parties in relation to the semaglutide project.

Brian
24:56 - 25:19

Got it. Um, and then just, thirdly, on the GEP-NET study phase three that you got, first half of 25. Um, can you just help us understand how the tougher patient population in the Sorrento study could mean that the comparator arms of Saturn and some actually could potentially underperform versus what we've seen historically from their phase three studies. Thank you.

John
25:21 - 26:42

Yeah, we are not assuming the performance is from this for the comparator arm. And of course it depends on which study you are referring to. But definitely if you're referring to the Clarinet study which Ipsen performed. Uh, yes. I mean, there you have a progression-free survival, which was very long. I would say that in that study, it was essentially a large majority of patients were grade one patients, with low proliferation rates when it comes to tumor proliferation. So below two, we have a much broader and in a sense, more representative population in Sorrento, with a majority, actually, of grade two patients. So from that aspect, they have more advanced neuroendocrine tumor states. And uh, we also have higher K 67 proliferation index values. So I think that's the basis that we have had in our assumptions. And I think the population we assumed when we started the study is very much reflecting the population that we now have in the study after recruiting all patients. Okay. Anything else? Brian?

Brian
26:43 - 26:44

Great. That's fantastic.

Annette
26:47 - 26:52

The next question is from a segment from Handelsbanken. Please go ahead. Your line is open.

26:55 - 27:48

Yeah. Thanks so much for taking my question. I have two questions, please. So on my calculations, sales in your largest market, Australia, declined in local currencies by 14% sequentially during the quarter. You referred to inventory fluctuations. But can you share what in-market sales growth you saw in Australia? Or was there any additional dynamic in the quarter that explained the performance in Australia? And then, secondly, I guess on the monthly CMA, can you say anything? Why now? Because GLP-1 and analogs have been listed for molecular classes where fluid crystals are applicable in presentations. I think back to all of the events since 2018. So have you achieved a technology breakthrough that you couldn't accomplish before, or is it the time left on the IP that has now accelerated this program?

27:51 - 27:51

Okay.

John Gray
27:52 - 28:23

Thank you. Regarding your question about the late reporting rate, it is correct. If we look at the in-market performance excluding the FX impact and consider the seasonality of the stocks, let's remember that Australia is going through a change in the supply model at the moment. The in-market trend that we see in the Australian market is in the range of 8%. And the second question is about a technology breakthrough.

John
28:23 - 28:24

And that's a plus.

John Gray
28:25 - 28:28

Yeah, it's plus 8 percent. Yeah.

John
28:28 - 29:17

So yeah, when it comes to the breakthrough in this case, first of all, I should say that we have been working with this program for some time. I cannot go into details about that. We have made significant optimization efforts and, of course, conducted quite a number of studies. So, when we are speaking about this time, it was more because we have taken the decision to move ahead towards the clinic. We have optimized the formulation work, and we have obtained the pre-clinical data that was required for us to take the next step in various different preclinical settings and models.

29:21 - 29:23

That's clear. And then I have one follow-up question.

John
29:23 - 29:59

I know regarding the intellectual property question. Semis, as we understand it, depend on geography, but it's an interesting time range. 2029 I think the original patent expires, but they have a patent extension that goes to 2032. Um, we'll see how that will finally pan out. But it's a good time. Uh, and face, um, to, to look into this development.

30:03 - 30:33

Thank you. That's clear. That's clear. Oh, rather unrelated to this, but returning to the impressive ramp-up and royalty generation in the first quarter. So is there any risk that there is some kind of stockpiling in Q1, Q3 that drove this three times sequential increase? Uh, I guess another way of asking is the royalty triggered by sales into the channel, including potential stockpiling, or is it driven by in-market sales?

John Gray
30:37 - 30:54

The reality is not driven by what is put into the channel; it is what the channel is distributing to their customers. This doesn't mean that all the merchandise can be distributed to patients, because there can be a small deposit in the channel. So, and I'm trying to reply to your question, Matthias.

John
30:55 - 31:22

But, if we delve into this question, I don't think there is any tendency, um, that this should represent a large stock-up; on the contrary, the patient numbers that have been provided by Braeburn, are reflective of the fact that the stock is being used in the market and is clear.

31:22 - 31:24

That's very clear. Thanks so much.

John
31:25 - 31:26

Okay. Thank you.

Annette
31:28 - 31:33

The next question is from Maria Vara from Bryan Garnier and Company. Please go ahead. The line is open.

Maria Vara
31:36 - 31:54

Hello. Good afternoon. Thank you for taking my question. I just wanted to have a bit of an update on the build-up of the US organization and Salesforce. How is this moving along in regards to the launch of CAM2029 in the US? You may remind us of the sales reps that you will be targeting. Thank you.

John
31:58 - 32:31

So yes, we are going ahead, and it's going very well. Right now, our focus is very much on the medical affairs side. Um, and of course, the whole system backup. Uh, so we have everything from compliance to other functions that are now put in place in the US. In terms of the strategy going forward, I think I'll hand it over to John. Maybe you can just give a summary of where we are with the strategy of the sales strategy in the US.

John Gray
32:31 - 33:29

Yes. So in terms of the strategy and sales team, we are going to build it up in a phased site. We are bringing in, and we already have, as has been disclosed, our US president. But we also have the head of marketing and sales. What will be in the market. And right now we are working in parallel to start developing, uh, so the product will be distributed into the market. So supply chain model patient model and which are the partners that they are going to support uh into this area. In parallel, we are working quite intensively with payers to try to ensure that the product can be accessed as soon as possible in the market. And that's where our focus for I would say Q2 and Q3. Then after that, all the cell phones will be on board, and we are trying to work ahead of the day to identify the relevant talent that can join our company.

John
33:30 - 34:08

And I think adding to that, of course, you also asked about, uh, you know, the, the, um, the targeting of the product in the market. And we have been working very intensively on that, uh, both on studies and we have had a number of, uh, regional studies performed, uh, identifying the prescribers and, and also the centers of, of largest interest. Uh, so, so that is an activity that has been prioritized. And we are continuing. Any further questions from you, Marianne?

Maria Vara
34:08 - 34:12

Yeah, great. That's super helpful. Thank you. That's all from my side. Yeah.

Annette
34:14 - 34:18

The next question is from Kristoffer from SCB. Please go ahead.

Kristoffer
34:21 - 34:51

Um, Hi there. Thanks for taking my questions. Uh, so you've previously enumerated why 2024 will be back-end loaded, and yet in Q1, you've delivered in line with the midpoint of top-line guidance. So why have you not raised the guidance? Uh, should we interpret this to mean that you're less confident about the favorable factors impacting market access and reimbursement in the EU five, um, actually transpiring than you maybe were previously? Uh, that's my first question.

John
34:53 - 35:27

For Christopher, I think. I mean, what we are saying and we're communicating is that we are basically tracking along the mid of our guidance. Uh, that's the results, um, that we have provided now. And if you're looking, I mean, obviously we will have different models, but I think we have not found a reason to change our guidance, uh, at this point. And we are expecting to follow this, uh, track going forward. I mean, John, do you have anything that you would like to add there? No.

John Gray
35:27 - 36:33

Uh, so far, our major investment areas in the US are public information. We disclose that we intend to increase our investment level by $300 million, mostly related to the US. And we are progressing in line with our activities. So the investment will increase, especially in the second half of the year. And right now we are aligned with the guidance we have provided on the top line. If I remember correctly, our company revenue has grown 37%, which is exactly the midpoint of providing guidance for the full year, 33% to 42%. And it is true that our profit before taxes has been strong compared to what the market was expecting, at $97 million. But still, we have nine months to go, and we expect to reach the investment of slightly above 1.3 billion. So we provide it in our guidance. So right now it is the first quarter. Three months have started, and we don't see solid results to change our guidance.

Kristoffer
36:35 - 37:24

Okay, great. And then I guess my second question would be, so one of your competitors recently talked about partnerships with pharmacy grocery chains to enable patients to administer the product in more convenient locations. So I guess closer to patients' homes. Is this something that you guys are working on? Do you see it as a potential key driver, or is it just one more piece of the puzzle? And then I guess while I'm still on the subject of the audio, in terms of competition, in some of your early launch markets, you now have more competition than you had before, perhaps. More than you had before, perhaps. To what extent are you feeling or noticing this impact?

John
37:28 - 37:39

I think I didn't understand the last question. The end of that question. But can you repeat that? Yeah, sure. To what extent?

Kristoffer
37:40 - 37:47

Of competition. I guess you have other long-acting competitors. Okay. And, are you noticing it?

John
37:47 - 37:48

Okay. That is.

Kristoffer
37:48 - 37:49

I'm not sure what you're thinking.

John
37:49 - 40:13

That's a good point. That's a very good question. So yeah, I mean, we can start with that. I think that in most of our markets, or all of our markets, we haven't seen the competitive landscape change very significantly. I would say in any geographic territory. Yeah. So of course, for us it's a new situation, but otherwise, in the markets where we are very strong, like Finland, extremely strong. We continue to see growth. So which we, of course, are very happy with. And we haven't seen a big penetration of any competitor products yet when it comes to alternate pathways and distribution models in the US, I would say that we have developed the kind of pharmacy chain injection model, which is being used especially in the Australian territory because there were stock-up issues or capacity limitations in specialty clinics. And this model is being applied elsewhere. And I think there are very important groups here. And this is also an important initiative for patients. Um, in our different markets, uh, and, uh, similarly in the US. And I cannot speak about this topic here, but I understand that it is the model that Indivior is developing, for instance. And of course, it's reasonable to expect that other parties are using similar approaches. Um, but it is a very important thing because, I mean, we should optimize the pathways for these patients and make treatment as accessible as possible, um, both regionally and in the large cities. And I think there is a large possibility of just improving these systems going forward. So, I can only confirm the importance of this.

Kristoffer
40:13 - 40:38

Okay. Great. Thanks. Uh, and then I guess, uh, my last question would be about the pipeline. Um, what can you tell us about the additional GLP-1 analogs you're testing that you mentioned, including whether any is proprietary? Um, for semaglutide, would you seriously consider taking this to market without a partnership with Novo? Thanks. That's all for me.

John
40:40 - 41:09

Okay. And when? When it comes to the first question, I mean, we will, uh, communicate, you know, as we go along. Uh, specifics at this point, I think, are that it is not our intention. Um, but we have some interesting programs going forward. Uh, they are still a bit earlier in terms of development. So therefore we are not choosing to communicate. Um, you know, on that note. When it came. When was the second question?

John Gray
41:10 - 41:10

I don't.

John
41:10 - 41:53

Know. Oh, yes. I mean, uh, we have only decided to develop the product up to and beyond the first clinical trial, whether or not, you know, we would change our focus and do phase two or other long trials. This will be a topic for the future. But, uh, obviously we are not expecting to be marketing products for the large indications here. Uh, but this is something that we will think about and communicate going forward. But our primary intent is not to bring this to commercialization.

Kristoffer
41:56 - 41:56

Thanks very much.

John
41:56 - 41:59

I cannot comment on the Novo question.

Annette
42:01 - 42:07

The next question is from Joon who is calling from Thin Asset Management, please go ahead.

42:10 - 42:22

Hi there and thank you for taking my question. So first of all, congratulations on the quarter and particularly the development in the US. And I have two questions. So the first one is on the GLP-1 study related to Novo Nordisk.

42:22 - 42:23

And I guess the idea here.

42:23 - 42:26

Is to open up for monthly shots.

42:26 - 42:29

But are there also other benefits to this?

42:29 - 42:42

And can you say something about the potential? And secondly, I understand that the development in Buvidal may be affected by stocking. Is this again related to the development in your working capital for the quarter?

John
42:46 - 44:10

Okay. Uh, yeah. Well, uh, starting out with the first question about GLP-1. So of course, there are multiple considerations there. Uh, I mean, everything from the titration process up to therapeutic levels, or to, uh, so dosing increases to convenience of. Weekly or monthly treatments, and this is also dependent on the patient group, of course. Long duration programs have a specific and maybe the highest interest in groups where compliance is challenging. But, uh, I mean, as a general rule, the larger the time frame between administrations, the better for the patient, as long as you have the correct PK profile. So I think the benefits can be everything from compliance titration up to, uh, the efficacy, uh, and exposure range that you are able to cover with the product. So and we are of course looking into all of these aspects. I think the second question, I'll just leave over to John. Um, is that sufficient on the GLP-1? John.

44:11 - 44:12

Uh. All good.

Kristoffer
44:14 - 44:14

Um.

John Gray
44:15 - 44:32

And regarding working capital, the answer is yes. Partially the increase in our inventories is due to that. But also we have made a conscious decision to try to increase the stock levels in the raw materials aspect. So this is a conscious company's decision. So it's a combination of both.

44:34 - 44:35

Thank you very much.

44:35 - 44:36

That's all for me.

Annette
44:38 - 44:41

There are no more questions at this time, so I'll hand the word back to you, Frederick.

John
44:44 - 45:04

Okay. And thank you so much. I think what I want to say is thank you for joining this call, and I'm looking forward to giving you the next update on June 17th. So until then, have a great day and please enjoy the holidays if you have them coming up here.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…